Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Apr 16;10(5):1213–1219. doi: 10.1111/1759-7714.13071

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd

This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

PMC Copyright notice

Overall survival (OS) of patients with ALK‐positive non‐small cell lung cancer (NSCLC) treated with crizotinib. Kaplan–Meier curves of OS (a) in the primary‐resistant responder (PRR) versus long‐term responder (LTR) group, and (b–d) in the PRR group according to Eastern Cooperative Oncology Group performance status (ECOG PS) score, line of crizotinib treatment, and subsequent therapy after crizotinib progression, respectively, including ALK inhibitors (ALKis), chemotherapy, and best supportive care (BSC). PRR group, LTR group, ECOG 0‐1, ECOG 2‐3, First line, Non‐first line, ALKis, Chemotherapy, BSC.

Inline graphic — Overall survival (OS) of patients with ALK‐positive non‐small cell lung cancer (NSCLC) treated with crizotinib. Kaplan–Meier curves of OS (a) in the primary‐resistant responder (PRR) versus long‐term responder (LTR) group, and (b–d) in the PRR group according to Eastern Cooperative Oncology Group performance status (ECOG PS) score, line of crizotinib treatment, and subsequent therapy after crizotinib progression, respectively, including ALK inhibitors (ALKis), chemotherapy, and best supportive care (BSC). PRR group, LTR group, ECOG 0‐1, ECOG 2‐3, First line, Non‐first line, ALKis, Chemotherapy, BSC.